Home›Clinical trials›Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist
Enrolling now · NCT07446998

A study testing whether a GLP-1 medicine from Veru, semaglutide, can help with weight.

What this means for you

Who can join
Adults 65 to 100, have obesity or are overweight, BMI 35+.
What you take
semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 1.8 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 2Sponsor Veru Inc.Drug semaglutideClass GLP-1 RASites 10 USEnrollment target 200

What this study is for

Primary condition: Obesity & Overweight. Also studied in: Mobility Disability, HOMA-IR.

Full scientific study title: Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist.

Who can join

Age65 to 100SexAnyBMI35 or higher

Adults 65 to 100, have obesity or are overweight, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Subjects accepted for this study must:
  • Provide informed consent from the subject or the subject's legally authorized representative
  • Be able to communicate effectively with the study personnel
  • Be >=65 years of age at the time of screening
  • For Female Subjects Menopausal status

Key exclusion criteria

  • Known hypersensitivity or allergy to enobosarm or a GLP-1 receptor agonist
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as measured using the chronic kidney disease-epidemiology collaboration (CKD-EPI) calculation (patients with mild and moderate renal failure are not excluded from participation in this study)
  • Treatment with any investigational product within < 5 half-lives for each individual investigational product OR within 30 days prior to randomization
  • Major surgery (the surgery poses a significant risk to patients life and requires general anesthesia) within 30 days prior to randomization
  • Planned major surgery during the course of the study or any cosmetic surgery potentially impacting body composition, e.g., liposuction, implants, or removal of any current implants

Where this study is enrolling

This trial has 10 sites across 6 states. Contact a site coordinator directly to start screening.

Arizona1 site
Florida5 sites
Georgia1 site
Louisiana1 site
Maryland1 site
Mississippi1 site

Timeline

Started enrolling: 2026-03-26. Expected completion: 2027-12. Last updated on ClinicalTrials.gov: 2026-04-22.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.